Skip to content

Study · Randomized controlled trial · 1997

7 results

Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study.

Freeman EW, Sondheimer SJ, Rickels K

Psychopharmacology bulletin1 Jan 1997Cited by 62 (Europe PMC)

PMID9230648 (opens in a new tab)PepBankPUB-09230648
Publisher pageAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with PMS, leuprolide significantly improved symptoms compared with placebo.

    In plain wordsIn women with PMS, leuprolide improved symptoms more than placebo.

    Peptide
    Leuprolide
    Outcome
    DecreasePMS symptoms
    Study

    n: not reported in source

    Comparator
    PMS placebo group
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.75 mg once a month · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The PMS leuprolide subjects improved significantly compared with the PMS placebo and PME leuprolide groups.
    2 context sentences
    Summary · context
    This randomized, placebo-controlled study examined the efficacy of the GnRH agonist, leuprolide acetate depot, in a clearly defined PMS sample versus women with premenstrual symptoms in combination with dysphoric symptoms throughout the cycle, termed the premenstrual exacerbation (PME) group.
    Summary · context
    Thirty-three eligible women were randomized to double-blind treatment and administered 3.75 mg of depot leuprolide or a placebo once a month for 3 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with dysphoric symptoms throughout the cycle, symptoms did not improve during leuprolide treatment.

    In plain wordsIn women with ongoing dysphoric symptoms, symptoms did not improve from baseline during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    No significant changeSymptoms in PME group
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.75 mg once a month · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The PME leuprolide group, who had dysphoric symptoms throughout the cycle, did not improve.
    2 context sentences
    Summary · context
    This randomized, placebo-controlled study examined the efficacy of the GnRH agonist, leuprolide acetate depot, in a clearly defined PMS sample versus women with premenstrual symptoms in combination with dysphoric symptoms throughout the cycle, termed the premenstrual exacerbation (PME) group.
    Summary · context
    Thirty-three eligible women were randomized to double-blind treatment and administered 3.75 mg of depot leuprolide or a placebo once a month for 3 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with PMS, premenstrual depression symptoms at clinical levels remitted following treatment in the PMS group; the abstract does not separate leuprolide from placebo recipients.

    In plain wordsIn women with PMS, depression symptoms before periods remitted after treatment in the PMS group; the abstract does not separate leuprolide from placebo.

    Peptide
    Leuprolide
    Outcome
    DecreasePremenstrual depression in PMS group
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.75 mg once a month · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Depression symptoms were at clinical levels premenstrually in the PMS and PME groups; following treatment they remitted in the PMS group but not in the PME leuprolide subjects.
    2 context sentences
    Summary · context
    This randomized, placebo-controlled study examined the efficacy of the GnRH agonist, leuprolide acetate depot, in a clearly defined PMS sample versus women with premenstrual symptoms in combination with dysphoric symptoms throughout the cycle, termed the premenstrual exacerbation (PME) group.
    Summary · context
    Thirty-three eligible women were randomized to double-blind treatment and administered 3.75 mg of depot leuprolide or a placebo once a month for 3 months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with PME receiving leuprolide, clinically elevated premenstrual depression symptoms did not remit after treatment.

    In plain wordsIn women with ongoing dysphoric symptoms receiving leuprolide, premenstrual depression symptoms did not remit compared with pretreatment.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedPremenstrual depression in PME group
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.75 mg once a month · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Depression symptoms were at clinical levels premenstrually in the PMS and PME groups; following treatment they remitted in the PMS group but not in the PME leuprolide subjects.
    2 context sentences
    Summary · context
    This randomized, placebo-controlled study examined the efficacy of the GnRH agonist, leuprolide acetate depot, in a clearly defined PMS sample versus women with premenstrual symptoms in combination with dysphoric symptoms throughout the cycle, termed the premenstrual exacerbation (PME) group.
    Summary · context
    Thirty-three eligible women were randomized to double-blind treatment and administered 3.75 mg of depot leuprolide or a placebo once a month for 3 months.
  5. 05HumanNon-randomized trialSafety outcome

    In women treated with leuprolide, there was no evidence of worsening PMS symptoms at treatment onset.

    In plain wordsIn women treated with leuprolide, PMS symptoms showed no evidence of worsening from pretreatment at treatment onset.

    Peptide
    Leuprolide
    Outcome
    No significant changeInitial worsening of PMS symptoms
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.75 mg once a monthAs given in this study (human).

    Source sentences

    Summary
    Efficacy did not occur until after several months of leuprolide treatment, but there was no evidence that PMS symptoms worsened with the onset of treatment.
    2 context sentences
    Summary · context
    This randomized, placebo-controlled study examined the efficacy of the GnRH agonist, leuprolide acetate depot, in a clearly defined PMS sample versus women with premenstrual symptoms in combination with dysphoric symptoms throughout the cycle, termed the premenstrual exacerbation (PME) group.
    Summary · context
    Thirty-three eligible women were randomized to double-blind treatment and administered 3.75 mg of depot leuprolide or a placebo once a month for 3 months.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women studied for premenstrual symptoms, leuprolide efficacy did not occur until after several months of treatment.

    In plain wordsIn women studied for premenstrual symptoms, leuprolide efficacy began only after several months of treatment.

    Peptide
    Leuprolide
    Outcome
    Not applicableOnset of efficacy
    Study

    n: not reported in source

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.75 mg once a month · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Efficacy did not occur until after several months of leuprolide treatment, but there was no evidence that PMS symptoms worsened with the onset of treatment.
    2 context sentences
    Summary · context
    This randomized, placebo-controlled study examined the efficacy of the GnRH agonist, leuprolide acetate depot, in a clearly defined PMS sample versus women with premenstrual symptoms in combination with dysphoric symptoms throughout the cycle, termed the premenstrual exacerbation (PME) group.
    Summary · context
    Thirty-three eligible women were randomized to double-blind treatment and administered 3.75 mg of depot leuprolide or a placebo once a month for 3 months.
  7. 07HumanObservational studyEfficacy outcome

    Among leuprolide recipients, women with PMS improved significantly more than women with ongoing dysphoric symptoms.

    In plain wordsAmong leuprolide recipients, women with PMS improved more than women with ongoing dysphoric symptoms.

    Peptide
    Leuprolide
    Outcome
    DecreasePMS symptoms by baseline dysphoria group
    Study

    n: not reported in source

    Comparator
    PME leuprolide group
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.75 mg once a month · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The PMS leuprolide subjects improved significantly compared with the PMS placebo and PME leuprolide groups.
    2 context sentences
    Summary · context
    This randomized, placebo-controlled study examined the efficacy of the GnRH agonist, leuprolide acetate depot, in a clearly defined PMS sample versus women with premenstrual symptoms in combination with dysphoric symptoms throughout the cycle, termed the premenstrual exacerbation (PME) group.
    Summary · context
    Thirty-three eligible women were randomized to double-blind treatment and administered 3.75 mg of depot leuprolide or a placebo once a month for 3 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.